Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

Biogen Inc BIIB shares are up sharply Friday after the company announced a delay in the FDA decision for its Alzheimer's treatment candidate, aducanumab.

What Happened: The FDA has extended the review period for the biologic license application for aducanumab by three months, Biogen and Eisai Co., Ltd ESALY said in a statement.

Biogen is co-developing aducanumab with the Japanese pharma company.

Biogen, the sponsor of the BLA, said it submitted a response to an information request by the FDA that included additional analyses and clinical data. The regulatory agency, deeming the submission as a major amendment to the application, extended the review period to give time for review.

The PDUFA goal data now stands postponed from March 7 to June 7.

Why It's Important: The positive stock reaction to the delay in decision is apparently a relief rally, as investors were positioning for a rejection following a negative Adcom verdict issued in early November.

After nearly shelving the development of aducanumab for Alzheimer's disease, Biogen resurrected the clinical program following subset analysis of data.

The company made a regulatory submission in July and the FDA accepted the application for priority review in August, assigning a PDUFA goal date of March 7.

Analysts are optimistic that the drug will ultimately clear the regulatory hurdle, given there is a serious unmet need and that there are no FDA-approved therapies to treat the disease per se.

In premarket trading, Biogen shares were advancing 11.69% to $299.18 and Eisai was advancing 3.26% to $77.05.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralAducanumabAlzheimer’s Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!